Uncategorized

Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrapped

Published

on

Sanofi had hoped the acquisition of Kymab would fill a major hole that will be left as autoimmune juggernaut Dupixent heads toward a patent cliff. Now, another therapy has failed to meet expectations.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version